IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site.  In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.

IMUNON

Douglas V Faller

This department provides expert guidance and strategic oversight on scientific and technological initiatives.

Advisory Board

This department manages and oversees clinical trials and ensures compliance with regulatory standards in clinical manufacturing processes.

Clinical Operations

This department focuses on optimizing and enhancing the effectiveness of various operational processes within the organization.

IMUNON

Org chart

Teams

Advisory Board

Clinical Operations

Strategic Operations

Offices

IMUNON

Org chart

Teams

Advisory Board

Clinical Operations

Strategic Operations

Offices

Related companies